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Solute carriers are a large class of transporters that play key roles in normal
and disease physiology. Among the solute carriers, heteromeric amino-acid
transporters (HATs) are unique in their quaternary structure. LAT1–CD98hc, a
HAT, transports essential amino acids and drugs across the blood–brain barrier
and into cancer cells. It is therefore an important target both biologically and
therapeutically. During the course of this work, cryo-EM structures of LAT1–
CD98hc in the inward-facing conformation and in either the substrate-bound or
apo states were reported to 3.3–3.5 A˚ resolution [Yan et al. (2019), Nature
(London), 568, 127–130]. Here, these structures are analyzed together with our
lower resolution cryo-EM structure, and multibody 3D auto-reﬁnement against
single-particle cryo-EM data was used to characterize the dynamics of the
interaction of CD98hc and LAT1. It is shown that the CD98hc ectodomain and
the LAT1 extracellular surface share no substantial interface. This allows the
CD98hc ectodomain to have a high degree of movement within the extracellular
space. The functional implications of these aspects are discussed together with
the structure determination.
1. Introduction
Solute carriers (SLCs) are an important class of membrane
proteins that are involved in the transport of nutrients,
signalling molecules and various metabolites as well as drugs
and their catabolites. They play key roles in human health and
disease and are important for normal and aberrant physiology.
Compared with other gene families of similar size and
physiological relevance, the function and molecular mechan-
isms of SLC transporters are poorly understood, in part owing
to a lack of structural information (Ce´sar-Razquin et al., 2015;
Bai et al., 2017). Heterodimeric amino-acid transporters
(HATs) are rare among the estimated 400 SLC transporter
genes annotated in the human genome (Schlessinger et al.,
2010). There are seven HATs with subunits belonging to the
slc3 and slc7 gene families, each with different functionality.
SLC3A1 and SLC3A2 are the heavy chains of the HATs,
which act as chaperones for the translocation of SLC7-family
transport-active light chains to the plasma membrane.
SLC3A2, also known as CD98hc or 4F2hc, forms hetero-
dimers with SLC7A5–SLC7A8 and SLC7A10–SLC7A11,
while SLC3A1 complexes with SLC7A9 (Fotiadis et al., 2013;
Deve´s & Boyd, 2000). The two HAT subunits are linked
together by a disulﬁde bridge between a conserved cysteine in
the loop between transmembrane helices 3 and 4 of the light
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chain and a conserved cysteine in the heavy chain (Fotiadis et
al., 2013; Deve´s & Boyd, 2000).
The L-type amino-acid transporter 1/SLC7A5 (LAT1) is a
55 kDa polytopic integral membrane protein that has been
shown to function as an Na+-independent secondary active
antiporter of neutral l-amino acids and in some cases their
catabolites. Substrates of LAT1 include leucine, isoleucine,
valine, phenylalanine, tyrosine, tryptophan, methionine and
histidine (Mastroberardino et al., 1998; Kanai et al., 1998).
CD98hc is a 68 kDa type II glycoprotein that functions as a
chaperone for LAT1, stabilizing and facilitating its transloca-
tion to the plasma membrane (Nakamura et al., 1999). LAT1 is
expressed in a number of tissues throughout the body (in
descending magnitude of expression: foetal liver, placenta,
brain, testis, bone marrow and leucocytes), whereas CD98hc
has been reported to be expressed more ubiquitously (Yana-
gida et al., 2001). The expression of LAT1–CD98hc in placenta
has been hypothesized to be essential for foetal development
owing to its role in the uptake of essential amino acids and
thyroid hormones (Ritchie & Taylor, 2001). Moreover, an
increasing number of tumours have been shown to ectopically
express the LAT1–CD98hc complex (Zhao et al., 2015; Cantor
& Ginsberg, 2012). It has been hypothesized that CD98hc
plays a similar role in cancer cells as in lymphocyte activation,
which is the ampliﬁcation of 1 and 3 integrin signalling,
reducing anchorage dependence and promoting cell prolif-
eration by modulating cyclin-dependent kinase regulation
through ERK signalling (Cantor & Ginsberg, 2012). More-
over, the transport activity of LAT1–CD98hc has been shown
to be pro-tumorigenic (Napolitano et al., 2015). LAT1
substrates are necessary for protein synthesis and for the
replenishment of the tricarboxylic acid cycle intermediates
that are used in the synthesis of other macromolecules such as
nucleotides, as is required for the survival and dysregulated
proliferation of tumour cells (DeBerardinis et al., 2007).
Leucine, which is one of the substrates of LAT1, is sensed by
sestrin2, leading to the activation of mTORC1, which in turn
promotes cell growth while inhibiting autophagy (Saxton et al.,
2016; Nicklin et al., 2009; Walls et al., 2016). LAT1 has also
been shown to transport drugs such as l-DOPA and gaba-
pentin across the blood–brain barrier (BBB; Dickens et al.,
2013; Kageyama et al., 2000). It is estimated that only 2% of
small-molecule drugs can cross the BBB. Central nervous
system penetrance therefore poses a signiﬁcant hurdle for the
development of small-molecule therapeutics for neurological
diseases (Pardridge, 2005). LAT1–CD98hc is thus an impor-
tant drug target for chemotherapy and drug delivery.
Structures of LAT1–CD98hc in the inward-facing confor-
mation at 3.3 and 3.5 A˚ resolution have recently been
reported,1 revealing extensive interaction between the trans-
membrane and intracellular domains of CD98hc and LAT1,
with limited interaction between the ectodomain and LAT1.
The transmembrane interaction region is mediated by direct
hydrophobic protein–protein contacts along the length of the
helices and indirectly by lipids. Yan et al. (2019) and Lee et al.
(2019) proposed that polar interactions between the extra-
cellular domain of CD98hc and the extracellular surface of
LAT1 would have important consequences for transport.
Similarly, Rosell and coworkers combined in silico docking of
the CD98hc crystal structure and a homology model of LAT2
with mutagenesis and cross-linking experiments and proposed
an extensive dimer interface, with the CD98hc ectodomain
covering 1735 A˚2 of the extracellular face of LAT2. This
extensive interaction was suggested to be the mechanism by
which CD98hc stabilizes LAT2 and has been assumed to be
the same for other light chains such as LAT1 (Rosell et al.,
2014; Dickens et al., 2017).
We have previously reported the kinetic and thermo-
dynamic stabilization of detergent-solubilized LAT1–CD98hc
by cholesterol hemisuccinate, which has proven to be impor-
tant for cryo-EM studies (Newstead, 2019). Here, we report on
the dynamics of LAT1–CD98hc observed by single-particle
cryo-EM, revealing ﬂexibility in the interaction between the
two subunits on the extracellular side.
2. Methods
2.1. Purification
LAT1–CD98hc was expressed and puriﬁed as reported
previously and immunoblotting was performed in the same
manner (Dickens et al., 2017). Brieﬂy, HEK293 suspension-
adapted and GNTI (HEK293SG) cells stably overexpressing
V5 epitope-tagged LAT1 were lysed by sonication in
Dulbecco’s phosphate-buffered saline pH 7 with 1 mM sodium
aurothiomalate. Crude membranes were prepared from the
cells by ultracentrifugation and were solubilized overnight
with anti-V5 resin in 20 mM Tris–HCl, 300 mM NaCl, 10%
glycerol supplemented with 0.9%(w/v) n-dodecyl -maltoside
(DDM), 0.19%(w/v) cholesteryl hemisuccinate Tris salt (CHS)
and 0.1%(w/v) lauryl maltose neopentyl glycol (LMNG). The
HAT complex was eluted from the resin using V5 peptide and
was then applied onto a Superdex 200 10/300 column in
100 mM Tris–HCl, 300 mM NaCl supplemented with 0.01%
DDM/CHS/LMNG in a 15:3:1 ratio before cryo-EM.
2.2. Grid preparation and data collection
Cryo-grids were prepared at 2.3 mg ml1. 3 ml aliquots were
applied onto glow-discharged Quantifoil Au R1.2/1.3 holey
carbon grids. The grids were plunge-frozen in liquid ethane
using a Vitrobot Mark IV (FEI), with grids blotted for 6 s at a
blot force of 6 and maintained at 100% humidity and 4C.
Data were collected using a Titan Krios microscope at eBIC
(Diamond Light Source) operating at 300 kV equipped with a
K2 Summit detector (Gatan) with the Volta phase plate
inserted. Automated data collection was performed with the
EPU software at a magniﬁcation of 47 710, using a defocus
value of 0.7 mm. A total of 2390 micrographs were collected
with a pixel size of 1.06 A˚. The total dose, 51 e A˚2, was
acquired using a dose rate of 4.96 e per pixel per second
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1 These structures appeared when our original manuscript was under
consideration by Nature Communications (submitted 4 March 2019). The
current article has been rewritten in view of the paper by Yan et al. (2019).
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across 40 frames for 12 s total exposure. Several data sets were
collected, at the University of Leeds Biostructure EM facility,
with and without the phase plate and in different buffer
conditions. Little difference was observed in the resultant
reconstructions and the best data set is reported and discussed
below. Data-collection parameters are given in Table 1.
2.3. Cryo-EM data processing
Whole-frame beam-induced motion correction and CTF
correction were performed using MotionCorr2 and Gctf
(v.1.06), respectively (Zheng et al., 2017; Zhang, 2016). Using
a box size of 200 A˚, 1388 particles were manually picked in
RELION-3 (Zivanov et al., 2018) and subjected to reference-
free 2D classiﬁcation to yield 2D classes for use as auto-
picking references. The 2D references were used to auto-pick
374 941 particles, giving an average of 157 particles per
micrograph. Using a previously generated initial 3D model
low-pass ﬁltered to 60 A˚, 3D classiﬁcation using all of the
particles was performed with two classes in order to remove
contaminants and false positives from auto-picking, while
reducing the risk of discarding poorly represented orientations
of the HAT. After visual inspection, 191 445 particles that
were in one of the two classes were chosen and subjected to
reference-free 2D classiﬁcation to yield 100 classes, the
majority of which were the protein–detergent complex. After
2D classiﬁcation of this particle set and 3D classiﬁcation of the
particles making up the best 2D classes, 77 423 particles
remained and were used in 3D auto-reﬁnement, yielding a 3D
single-particle reconstruction at 12 A˚ resolution after post-
processing and a B-factor sharpening of 1200 A˚2.
2.4. Interpretation of Coulomb potential maps produced by
single-particle reconstruction
Docking of the apo LAT1–CD98hc structure (PDB entry
6irs; Yan et al., 2019) was performed using the ‘Fit in map’ tool
in UCSF Chimera. The docking of the crystal structure of the
ectodomain of CD98hc (PDB entry 2dh2; Fort et al., 2007) into
the EM maps, after ﬁltering the crystal structure to 12 A˚
resolution, was performed by segmenting the map using the
SEGGER (v.1.9.4) tool with the map at a threshold of 0.00872;
the ‘Smoothing Steps’ parameter in SEGGER was set to ten
steps, while the other options were set to the default values
(Pintilie et al., 2010). An apo-out open model of LAT1 was
docked into the map after segmenting at the same threshold
but with ‘Smoothing Steps’ set to 3. Several segments were
grouped to form a single segment that contained the density at
the centre of the larger lobe of the map. The model was ﬁtted
after ﬁltering to 12 A˚.
2.5. Multibody 3D auto-refinement
A two-body multibody reﬁnement was performed as a
continuation of the ﬁnal 3D auto-reﬁnement. The density
corresponding to the ectodomain of CD98hc was deﬁned as
body 1 and the micellar density as body 2. Density maps for
mask creation were created by segmenting the 12 A˚ resolution
map using SEGGER into two densities corresponding to each
body to be reﬁned; the map segments were Gaussian-ﬁltered
using the ‘Volume Filter’ tool and resampled using the vop
command onto the same grid as the 12 A˚ resolution map using
UCSF Chimera. These map segments were then low-pass
ﬁltered with 30 A˚ and 11 A˚ soft edges added in RELION-3 to
create the masks used in the reﬁnement. The body.star ﬁle
was set up as described by Nakane et al. (2018). Principal
component analysis was performed on the orientations of both
bodies, and movies for the ﬁrst three principal components
(PCs) were written out as a series of volumes in MRC format
(Crowther et al., 1996) describing the relative motion of the
two bodies as described by these PCs. The ‘Volume series’ tool
ofUCSF Chimera was used to visualize the movies and the ‘Fit
in map’ tool was used to ﬁt CD98hc ectodomain and the
transmembrane domains of LAT1–CD98hc from the structure
with PDB code 6irs or the homology model of LAT1 in each of
the volumes before saving each as a PDB ﬁle to be used for
ensemble analysis using the ‘MD movie’ tool in UCSF
Chimera.
2.6. Modelling LAT1 and docking of the CD98hc ectodomain
The sequence of LAT1 (NCBI accession No. NP_003477.4)
was submitted to the HHpred server (So¨ding et al., 2005) to
search for homology-modelling templates in the Protein Data
Bank using default parameters. The apo outward-facing
structure of AdiC from Escherichia coli (PDB entry 5j4i; Ilgu¨
et al., 2016) was chosen as a template for modelling LAT1
using MODELLER v.9.19 (Webb & Sali, 2016). Ten decoys
were generated and the decoy with the lowest DOPE (discrete
optimized protein energy) score was carried forward for
optimization via ModReﬁner using a template (Xu & Zhang,
2011). The CD98hc ectodomain (PDB entry 2dh2) and LAT1
were docked using ClusPro (Kozakov et al., 2017). Distance
restraints were provided based on LAT2 cross-linking
experiments and the conserved inter-subunit disulﬁde bond
(Supplementary Fig. S1). The LAT1 sequence was also
submitted to ConSurf (Ashkenazy et al., 2016) for conserva-
tion analysis using default settings.
3. Results
3.1. Struture and inter-domain dynamics of LAT1–CD98hc
LAT1 was stably expressed in HEK293SG cells and endo-
genous CD98hc was upregulated in response, as reported
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Table 1
Data-collection parameters.
Microscope and detector Titan Krios with K2 Summit (Gatan)
Voltage (kV) 300
Phase plate Yes
Pixel size (A˚) 1.06
Defocus (mm) 0.7
Total dose (e A˚2) 51
No. of frames 40
Dose per frame (e A˚2) 1.27
No. of micrographs 2390
Total auto-picked particles 374941
Particles in ﬁnal reﬁnement 77423
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previously (Khunweeraphong et al., 2012; Dickens et al., 2017).
Sodium aurothiomalate was added to the lysate to prevent
reduction of the conserved inter-subunit disulﬁde bond, and
immunoafﬁnity was used to purify the heteromeric complex
after detergent solubilization [Figs. 1(a), 1(b) and 1(c)]. Size-
exclusion chromatography yielded a major peak eluting at
10.5 ml, which was determined to be LAT1–CD98hc with an
intact inter-subunit disulﬁde bond. This product was of sufﬁ-
cient purity for structural characterization by cryo-EM
[Figs. 1(b), 1(c) and 1(d)].
Single particles visible in the micrographs were consistent
with a homogeneous sample of a 123 kDa protein–detergent
complex and showed a clear bilobed structure [Fig. 2(a)].
2D classiﬁcation revealed an asymmetric bilobed structure
[Fig. 2(b)] similar to those observed in the recently reported
cryo-EM structures of the LAT1–CD98hc complex in similar
detergent conditions [Fig. 2(b)] (Yan et al., 2019). The larger
lobe had an ellipsoidal geometry characteristic of the
n-dodecyl maltoside and cholesterol hemisuccinate micelles
(DDM/CHS) used here to purify and stabilize LAT1–CD98hc
(O’Malley et al., 2011; Dickens et al., 2017). 3D reconstruction
from this data set yielded an 12 A˚ resolution map of the
transporter complex as determined by gold-standard Fourier
shell correlation (FSC; 0.143 cutoff) [Fig. 2(d)]. One of the
high-resolution strutures of LAT1–CD98hc (PDB entry 6irs)
was docked into the map, with the ectodomain of CD98hc
occupying the smaller lobe and the transmembrane regions of
the two subunits occupying the detergent micelle density
[Fig. 2(b)]. The crystal structure of the CD98hc ectodomain
(PDB entry 2dh2) was docked into the smaller lobe of the EM
envelope after two-multibody 3D auto-reﬁnement as
described below. The depression at the centre of the triose-
phosphate isomerase-like barrel in the A domain of CD98hc
permitted orientation of the crystal structure in the EM map
accurately [Fig. 2(c)]. The larger lobe of the 3D reconstruction
had a ring of missing density which may represent the
boundary between the detergent micelle and the transmem-
brane domains of LAT1 and CD98hc [Fig. 2(b)]. There was no
density between the two lobes and most of the backbone of
the docked structures was accounted for by the density, indi-
cating the absence of extensive interaction between the two
subunits on the extracellular side [Fig. 2(b)].
To explore the ﬂexibility between the two lobes of the
LAT1–CD98hc structure, 3D multibody auto-reﬁnement was
performed. This was followed by principal component analysis
(PCA) as described by Nakane et al. (2018). PCA of the
variance in rotations and translations of the two bodies
deﬁned in the multibody reﬁnement was accounted for in 12
principal components (PCs), with the ﬁrst three accounting for
42.7% of the variance [Fig. 3(a)]. The distribution of variance
across the PCs shows a limited preference for variance along a
particular PC, suggesting almost independent movement of
the two lobes (Lever et al., 2017). In order to visualize the
molecular ﬂexibility between the two bodies, a volume series
consisting of ten volumes per component was rendered out for
the ﬁrst three components. The crystal structure of the
CD98hc ectodomain and the structure of the transmembrane
domains of the complex were docked into each volume of the
three series, allowing modelling of the ﬂexibility described by
their principal components in molecular terms. Component 1,
which described 18.7% of the variance, showed mostly trans-
lation but also some rotation of the CD98hc ectodomain and
LAT1 in opposite directions along parallel planes perpendi-
cular to the plane of the long axis of the complex [Fig. 3(b);
Supplementary Movie S1]. The second largest principal
component, which described 13.7% of the variance, showed a
forward, downward and slanted motion in the CD98hc ecto-
domain and a downward backward motion in LAT1, with the
effect of bringing the C domain of the CD98hc ectodomain
closer to LAT1 while lifting the A domain away in the ﬁnal
frame [Fig. 3(c); Supplementary Movie S2]. The third
component showed upward and downward motions in the
CD98hc ectodomain and a slight twisting motion in LAT1,
bringing the two closer to each other and then further apart
[Fig. 3(d); Supplementary Movie S3]. The unimodal distribu-
tion of particles along these principal components suggests
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Figure 1
Puriﬁcation of LAT1–CD98hc. (a) Immunoblot using anti-LAT1 poly-
clonal antibody under nonreducing conditions of HEK293 cells over-
expressing LAT1 that were lysed in the absence (lane 1) or presence (lane
2) of 1 mM sodium aurothiomalate. The two bands that are visible are
consistent with heterodimeric (123 kDa) and monomeric (55 kDa) LAT1.
(b) Size-exclusion chromatogram of LAT1–CD98hc after puriﬁcation by
immunoprecipitation on a Superdex 200 10/300 column at 0.4 ml min1.
The peak at a retention volume of 10.5 ml was used for cryo-EM. (c)
Coomassie-stained SDS–PAGE gel of puriﬁed LAT1–CD98hc (lane 2)
run under nonreducing conditions. (d) Coomassie-stained SDS–PAGE
gel of puriﬁed LAT1–CD98hc (lane 2) run under reducing conditions and
immunoblotted using anti-CD98hc monoclonal antibody (lane 3).
Molecular-weight markers are labelled on the left in kDa.
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that the motion along these principal components is contin-
uous [Figs. 3(b), 3(c) and 3(d)].
3.2. The role of intersubunit interaction in the transport
mechanism
In addition to the intersubunit disulﬁde bond, electrostatic
interactions between residues on the extracellular side of
LAT1 and the CD98hc ectodomain have been proposed to
stabilize the interaction between the two subunits (Yan et al.,
2019). However, there is no EM density in the maps of the 3.3
and 3.5 A˚ resolution structures corresponding to some of the
positions of the side chains of these putative interacting resi-
dues, and this may perhaps be why these residues have
different conformations in the two structures. This is particu-
lary striking for Gln304 and Glu303 in LAT1, which are
modelled on a helix for which there is no corresponding EM
density (PDB entry 6irs) [Figs. 4(a) and 4(b)]. The lack of
density in these regions of the map suggests ﬂexibility in these
residues, especially in the case of the helix bearing Gln304 and
Glu303 in LAT1. The average distances between the putative
interacting pairs, 3.5 A˚ from Arg535 (CD98hc) to Thr163
(LAT1), 5 A˚ from Arg535 to Gln304 and 4.4 A˚ from Lys533 to
Glu303, as well as the potentially attenuating effect of the
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Figure 2
Cryo-EM and single-particle reconstruction of detergent-solubilized LAT1–CD98hc. (a) Micrograph of LAT1–CD98hc collected with the Volta phase
plate after motion and CTF correction. The scale bar shown in the bottom left corner is 60 nm in length. The particles observed are consistent in size and
shape with a heterodimeric, 123 kDa complex in DDM/CHS. (b) Representative 2D classes of the particles of LAT1–CD98hc used in 3D reconstruction;
below, the resulting 3D map. The 2D classes and 3D map (mesh) are congruent and are characteristic of a HAT protein–detergent complex, with a small
extracellular density and a large ellipsoidal detergent belt. LAT1 (magenta) and CD98hc (blue; PDB entry 6irs) are shown as ribbon models docked into
the 3D map (EMD-4642). The particle box size was 200 A˚with a mask diameter of 180 A˚. (c) EM map density corresponding to the CD98hc ectodomain
after multibody reﬁnement with the crystal structure docked (PDB entry 2dh2). The A and C domains of CD98hc are coloured purple and red,
respectively. (d) Fourier shell correlation (FSC) curves for the consensus reconstruction and for the ectodomain and micelle reconstructions. The
resolution at a 0.143 FSC cutoff is 12 A˚ (consensus, blue), 11 A˚ (micelle, red) and 9 A˚ (ectodomain, green).
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solvent accessibility, are both consistent with a weak stabi-
lizing interaction, ﬂexibility in these residues and thus dynamic
interaction between LAT1 and the CD98hc ectodomain [Fig.
4(c)].
To explore whether the dynamics of LAT1–CD98hc inter-
action were particular to the inward-facing conformation
common to the high-resolution structures reported to date,
homology modelling was used to predict the structure of the
outward open conformation. Despite the low resolution of the
EM map, utilizing our knowledge of the extracellular local-
ization of the CD98hc crystal structure and the location of the
inter-subunit disulﬁde bond, as well as the orientation of
LAT1 in the membrane, we were able to dock a homology
model of LAT1 in the outward open conformation into the
map (Fig. 5). The distance between Cys164 in the outward
open model of LAT1 and Gly109, which substituted for
Cys109 in the CD98hc ectodomain structure, was found to be
15 A˚ in the EM-derived model [Figs. 5(a), 5(b) and 5(c)].
Various conformations of the loop were modelled to demon-
strate the plausibility of disulﬁde bonding between the HAT
subunits as docked in the EM map [Fig. 5(d)]. The volume
series showing the ﬂexibility of the interaction between the
CD98hc ectodomain and LAT1 was similarly interpretable
using the homology model as with the high-resolution struc-
ture, indicating that the dynamics are not speciﬁc to either the
outward open or inward open conformations of LAT1. This
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Figure 3
Two-body 3D auto-reﬁnement and principal component analysis of their rotations and translations. (a) Variance in the data set was captured in 12
principal components. The ﬁrst three components accounted for 42.7% of the variance, and volume series along these components were interpreted by
docking the CD98hc ectodomain and LAT1. Motion along the ﬁrst (b), second (c) and third (d) principal components (upper panel) and the histograms
of the amplitudes (lower panel) along them are shown. The ﬁrst and last frames of the volume series along each vector are coloured red and blue,
respectively.
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suggests that the dynamics of the extracellular side of the
complex do not play a role in the conformational changes of
LAT1 during its transport cycle.
It has been suggested that the ectodomain of CD98hc
interacts with the plasma membrane. Our analysis and the
high-resolution structures are based on detergent-solubilized
LAT1–CD98hc and therefore do not address the role of this
membrane interaction in the structure and function of the
complex (Fort et al., 2007). The extracellular face of LAT2 and
the ectodomain of CD98hc have been postulated to interact
extensively, with a predicted interface of 1735 A˚2, based on
cross-linking experiments performed in the native environ-
ment of the cell plasma membrane (Rosell et al., 2014). In all
of the reported structures of LAT1, LAT1 and the ectodomain
of CD98hc do not interact in the manner suggested for LAT2
(Figs. 2 and 3). Even though there are similar residues to those
predicted to be present at the interface of the CD98hc
ectodomain and LAT2 on the LAT1 extracellular face, some
of these residues are not conserved across LAT1 orthologues,
suggesting that they may not play signiﬁcant structural and or
functional roles [Fig. 6(a); Supplementary Table S2]. Docking
of the CD98hc ectodomain and LAT1 was attempted but
failed to give solutions that satisﬁed distance restraints derived
from the cross-linking of LAT2 and CD98hc in the plasma
membrane [Figs. 6(b) and 6(c)]. The distance between residues
that were positive in LAT2–CD98hc cross-linking experiments
were tracked across each frame of the volume series for PC1–
PC3. All residues tracked were >18 A˚ apart in all 30 frames of
the three major principal components [Fig. 6(d); Supplemen-
tary Table S2]. This was outside the range of the cross-linkers
used by Rosell et al. (2014) (3.5–14.3 A˚; Supplementary Table
S2).
4. Discussion
Heterodimeric transporters are rare among SLC transporters,
and the structural and functional signiﬁcance of this unique
quaternary structure remains to be thoroughly explored. We
report here the dynamical interaction of the ectodomain of
CD98hc and LAT1 as revealed by single-particle cryo-EM.
Two-body 3D auto-reﬁnement, followed by principal compo-
nent analysis (PCA) of the rotations and translations of
densities corresponding to the transmembrane domains/
detergent micelle and CD98hc ectodomain, revealed variance
within the 2D projections of the protein–detergent complex.
The ﬂexibility described in the ﬁrst three principal compo-
nents suggested that the CD98hc ectodomain does not interact
with LAT1 and is only tethered to LAT1 through interactions
of its transmembrane domain with those of LAT1 and by the
conserved inter-subunit disulﬁde bond. The hypothesis that a
weak noncovalent interaction exists between the heavy and
Figure 4
Interface of LAT1 and the CD98hc ectodomain. (a) Residues proposed to be involved in electrostatic interactions between the two subunits on the
extracellular side. CD98hc is shown in green and LAT1 is in cyan (PDB entry 6irt). The EM density map on which the model is based is shown as a mesh
(EMD-9722). (b) Side-chain conformations of these putatively interacting residues from the substrate-bound and inhibitor-incubated strutures of LAT1–
CD98hc (PDB entries 6irt and 6irs, respectively). (c) Surface of the extracellular interface of substrate-bound LAT1–CD98hc, highlighting the solvent-
accessibility of the interface. Putative interacting residues are showns as sticks.
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light chain in a HAT was ﬁrst put forward by Pfeiffer et al.
(1998) based on the results of mutagenesis and immuno-
precipitation experiments as well as the observation that the
disulﬁde bond between the subunits is highly conserved.
K533E and E303K mutations in CD98hc have previously been
shown to reduce transport, which was interpreted as indicating
the importance of putative interactions on the extracellular
side of the complex to function (Yan et al., 2019). In silico
mutagenesis of these residues indicates that they are likely to
create steric clashes across the extracellular interface.
We suggest, based on the analysis above, that the limited
interaction of the CD98hc ectodomain and LAT1 is inde-
pendent of the conformation of LAT1, at least with respect
to the open inward-facing and outward-facing conformations.
This is consistent with the ﬂexibility of the linker between the
transmembrane domain and the ectodomain of CD98hc and of
the loop region between transmembrane helices 3 and 4 of
LAT1, on which the conserved intersubunit disulﬁde bond is
located. Flexibility in this region may also allow some degree
of independence between the conformational dynamics of the
transmembrane domains, which are essential for the transport
cycle, and those of the ectodomain of the complex, as
discussed here. The solution of high-resolution strutures of the
complex in conformations other than the open inward-facing
would test this hypothesis, allowing further exploration of the
role of CD98hc in the transport mechanism of the complex.
An interaction interface between the CD98hc ectodomain
and LAT2 was proposed on the basis of docking and cross-
linking experiments by Rosell et al. (2014). LAT2 shares 52%
sequence identity with LAT1 and the residues at this interface
are similar; therefore, it had been assumed that LAT1 would
interact with the CD98hc ectodomain in a similar manner. Our
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Figure 5
Docking of LAT1 in the outward open conformation into a 12 A˚ resolution EM map. Side (a), front (b) and top (c) views of the docked EM map,
represented as a mesh with the CD98hc ectodomain crystal structure shown in blue and a homology model of LAT1 in pink, are shown. Asterisks mark
the positions of Gly109 in CD98hc and Cys164 in LAT1. (d) The interdomain linker, Gly109–Gly127, of CD98hc modelled to show the plausibility of
inter-subunit disulﬁde-bond formation between Cys164 of LAT1 and Cys109 of CD98hc (shown as sticks with S atoms in yellow) docked into the EM
map (shown as a mesh).
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data suggest a more ﬂexible interaction between the two
subunits. Our analysis is consistent with the recently reported
13 A˚ resolution cryo-EM structure of detergent-solubilized
LAT2–CD98hc and the recent 3 A˚ resolution structures of
LAT1–CD98hc (Jeckelmann & Fotiadis, 2019; Yan et al., 2019;
Lee et al., 2019). The cross-linking data on LAT2–CD98hc
were derived from a complex that was cross-linked in the
native environment of the plasma membrane. This may
explain some of the discrepancy between the cross-linking
data and the structure of the detergent-solubilized complexes
(Rosell et al., 2014), with detergent having been shown to
impact the interactions and dynamics of membrane proteins
(Chipot et al., 2018; Seddon et al., 2004). Therefore, an
important next step is studying the LAT1 structure and its
interactions in a more native lipid environment. We found no
evidence of dimers of heterodimers, as has been suggested in
the literature (Napolitano et al., 2017). Fort et al. (2007) put
forward a model for CD98hc homodimerization and plasma-
membrane interaction based on the crystal structures of the
ectodomain; if this model is correct then light chains such as
LAT1 perhaps disrupt or prevent the formation of CD98hc
homodimers (Fort et al., 2007). Given the variety of contexts in
which CD98hc is expressed, studying its oligomeric state in
each context and its impact on the function of the protein may
produce insights into the mechanisms of this glycoprotein.
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Comparison of the LAT1–CD98hc dimer interface predicted from homology to LAT2 with EM data. (a) Model of the CD98hc ectodomain (tan) and
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CD98hc ectodomain and LAT1 shows a similar orientation of subunits as in the consensus cryo-EMmap. (c) An in silico heterodimer model docked into
the last frame of the volume series of PC3. (d) The distance between the N atoms of residues of LAT1 (chain A) and CD98hc (chain B) across the frames
of a molecular-dynamics movie generated from the volume series along the ﬁrst three principal components describing the variance between LAT1 and
CD98hc in the EM data. The legend gives the residue name, chain and atom.
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